Want to see IKT full AI Analyst Report?
Top Page
Inhibikase Therapeutics
(NASDAQ:IKT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-39.76% Downside)
Action:Reiterated
Date:10/21/26
The score is held down primarily by weak financial performance (no meaningful revenue, widening losses, and significant cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting factors include a low-debt balance sheet and positive corporate developments around IKT-001 (Orphan Drug Designation and Phase 3 progress), but these do not outweigh the near-term funding and execution risks evident in the financials and price trend.
Positive Factors
Debt-Free Balance Sheet
Effectively zero debt limits interest expense and reduces solvency pressure while the company funds clinical development. This gives management greater flexibility to allocate capital toward IKT-001 and other research priorities, although it does not eliminate the need for future financing.
Negative Factors
No Commercial Revenue
The absence of meaningful revenue confirms that the company remains dependent on clinical execution before establishing a commercial business. Until a therapy is approved and launched, operating costs are unlikely to be supported by product sales, leaving financial performance highly sensitive to development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Effectively zero debt limits interest expense and reduces solvency pressure while the company funds clinical development. This gives management greater flexibility to allocate capital toward IKT-001 and other research priorities, although it does not eliminate the need for future financing.
Read all positive factors
Inhibikase Therapeutics (IKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$212.09M
Dividend YieldN/A
Average Volume (3M)663.38K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue GrowthN/A
EPS Growth59.89%
CountryUS
Employees35
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding139,535,900
10 Day Avg. Volume774,688
30 Day Avg. Volume663,380
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$5.50Price Target Upside120.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$285.71K
Inhibikase Therapeutics Business Overview & Revenue Model
Company Description
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threa...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Inhibikase Therapeutics does not typically generate recurring product revenue until it secures regulatory approvals and commercializes a drug; specific current product-sales revenue is not available (...
Inhibikase Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.Positive Updates
Completion of Phase II 201 Trial Enrollment
Inhibikase Therapeutics has completed enrollment for the Phase II 201 Trial for risvodetinib in Parkinson's disease, marking a significant milestone. Top line data from the trial is expected in November.
Negative Updates
Adverse Events in Phase II 201 Trial
In the Phase II 201 Trial, 41 mild and 8 moderate adverse events were observed that may be related to risvodetinib treatment, with 6 participants withdrawing from the trial.
Read all updates
Q2-2024 Updates
Positive
Negative
Completion of Phase II 201 Trial Enrollment
Inhibikase Therapeutics has completed enrollment for the Phase II 201 Trial for risvodetinib in Parkinson's disease, marking a significant milestone. Top line data from the trial is expected in November.
Read all positive updates
Company Guidance
During the Inhibikase Therapeutics Q2 2024 earnings call, executives highlighted several key metrics and developments. The company completed enrollment for the Phase II trial of risvodetinib in Parkinson's disease, expecting to report top-line data in November. They observed 49 adverse events and had six withdrawals from the trial. For their IkT-001Pro, a prodrug formulation aimed at pulmonary arterial hypertension (PAH), they filed an IND on August 9, 2024, with plans for a Phase IIb trial involving around 100 patients. Financially, Inhibikase reported a net loss of $5.0 million for the quarter, with R&D expenses decreasing by $1.5 million to $3.1 million, and a cash position of $7.9 million as of June 30, 2024. The company expects its cash runway to extend into December 2024, bolstered by raising $4 million in May from registered direct offering and concurrent private placement.Inhibikase Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 260.50K | 123.44K | 3.10M |
| Gross Profit | 0.00 | 0.00 | -26.27K | -13.36M | 116.72K | -8.26M |
| EBITDA | -62.34M | -53.29M | -27.49M | -18.85M | -18.05M | 0.00 |
| Net Income | -60.64M | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M |
Balance Sheet | ||||||
| Total Assets | 163.59M | 181.20M | 98.60M | 14.51M | 24.94M | 42.47M |
| Cash, Cash Equivalents and Short-Term Investments | 159.02M | 178.76M | 97.54M | 13.25M | 23.05M | 40.75M |
| Total Debt | 0.00 | 0.00 | 110.52K | 622.00K | 351.29K | 248.91K |
| Total Liabilities | 10.26M | 8.30M | 3.73M | 3.53M | 3.90M | 4.05M |
| Stockholders Equity | 153.33M | 172.90M | 94.87M | 10.98M | 21.04M | 38.42M |
Cash Flow | ||||||
| Free Cash Flow | -43.06M | -27.79M | -19.15M | -18.10M | -17.59M | -14.30M |
| Operating Cash Flow | -42.61M | -27.79M | -19.15M | -18.09M | -17.35M | -14.30M |
| Investing Cash Flow | -115.24M | 2.05M | -37.00M | 11.66M | -16.01M | 0.00 |
| Financing Cash Flow | 111.31M | 108.46M | 103.48M | 8.41M | -204.77K | 41.09M |
Inhibikase Therapeutics Technical Analysis
Negative
2.49
Price Trends
2.14
Negative
2.10
Negative
1.94
Negative
Market Momentum
-0.16
Positive
25.92
Positive
11.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IKT, the sentiment is Negative. The current price of 2.49 is above the 20-day moving average (MA) of 1.82, above the 50-day MA of 2.14, and above the 200-day MA of 1.94, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 25.92 is Positive, neither overbought nor oversold. The STOCH value of 11.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IKT.
Inhibikase Therapeutics Risk Analysis
Inhibikase Therapeutics disclosed 82 risk factors in its most recent earnings report. Inhibikase Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibikase Therapeutics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $62.31M | 7.64 | 16.17% | 0.52% | 26.04% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | $24.45M | -0.56 | -102.99% | ― | ― | -28.83% | |
49 Neutral | $101.86M | -9.61 | -70.44% | ― | ― | 10.04% | |
46 Neutral | $212.09M | -3.20 | -42.80% | ― | ― | 59.89% | |
46 Neutral | $320.64M | -0.66 | 187.62% | ― | -8.79% | -195.46% | |
40 Underperform | $12.86M | -0.21 | -108.72% | ― | 2.15% | 17.34% |
* General Sector Average
IKT
Inhibikase Therapeutics
1.52
-0.04
-2.56%
ATOS
Atossa Therapeutics
2.45
-11.70
-82.68%
ANIX
Anixa Biosciences
2.93
-1.40
-32.33%
SPRO
Spero Therapeutics
1.07
-1.22
-53.28%
SRZN
Surrozen
27.28
13.35
95.84%
TCRX
TScan Therapeutics
0.19
-2.09
-91.71%
Inhibikase Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Inhibikase Appoints Scott Wasserman to Board of Directors
Positive
Oct 20, 2026
On October 19, 2026, Inhibikase Therapeutics announced that board member Dennis Berman resigned from the board, as well as from his roles chairing the Compensation Committee and serving on the Audit Committee, with the company stating his departur...
Business Operations and StrategyProduct-Related Announcements
Inhibikase advances IKT-001 in pivotal PAH Phase 3
Positive
Sep 8, 2026
On September 8, 2026, Inhibikase Therapeutics updated its corporate presentation to highlight progress and positioning of IKT‑001 as a potential first once‑daily oral antiproliferative therapy for pulmonary arterial hypertension. The m...
Business Operations and Strategy
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
Neutral
Jul 29, 2026
On July 29, 2026, Inhibikase Therapeutics entered into an exchange agreement with RA Capital Healthcare Fund under which RA Capital swapped 18,030,000 shares of common stock for a pre-funded warrant to acquire an equal number of shares. The warran...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Inhibikase Gains FDA Orphan Drug Status for IKT-001
Positive
Jul 23, 2026
On July 23, 2026, Inhibikase Therapeutics announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to its lead candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.